Literature DB >> 32007599

Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.

Raj G Vaghjiani1, Yusuke Takahashi2, Takashi Eguchi3, Shaohua Lu4, Koji Kameda5, Zachary Tano1, Jordan Dozier1, Kay See Tan6, David R Jones1, William D Travis7, Prasad S Adusumilli8.   

Abstract

INTRODUCTION: In patients with stage IA lung adenocarcinoma (ADC), sublobar resection and tumor spread through air spaces (STAS) are associated with high rates of locoregional recurrence, half of which occur within the regional lymph nodes (LNs). Our objectives were to investigate the association between occult LN metastasis (ONM) and STAS and to assess their prognostic value in patients with clinical stage IA lung ADC.
METHODS: The association between STAS and ONM was analyzed in patients who underwent lobectomy and LN dissection for clinical stage IA lung ADC (n = 809). Multivariable logistic regression analysis was carried out to identify predictors of ONM. Site-specific recurrence by surgical procedure was investigated in patients with pathologic node-negative disease (n = 1055) using a competing risk approach.
RESULTS: ONM was identified in 129 patients (16%)-one-third of ONMs were located only in intrapulmonary nodes. STAS was more common in patients with ONM than in those without ONM (67% versus 39%; p < 0.001) and in patients with multiple ONMs than in those with a single ONM (86%-89% versus 60%-67%). STAS was a significant predictor of ONM (p = 0.004) on multivariable analysis, independent of tumor size, maximum standardized uptake value, and lymphovascular invasion. In patients with STAS-positive ADC (high ONM risk), the risk of recurrence in the treated lobe and regional LNs increased as the extent of resection decreased (recurrence risk: lobectomy < segmentectomy < wedge resection). In patients with STAS-negative ADC, the risk of locoregional recurrence did not differ by procedure type.
CONCLUSIONS: Presence of STAS predicts ONM in patients with clinical stage IA lung ADC and can help stratify risk of recurrence by extent and type of resection.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lung adenocarcinoma; Lymph node metastasis; NSCLC; Pathologic staging; Sublobar resection

Mesh:

Year:  2020        PMID: 32007599      PMCID: PMC7199202          DOI: 10.1016/j.jtho.2020.01.008

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  41 in total

1.  The importance of lymph node dissection accompanying wedge resection for clinical stage IA lung cancer.

Authors:  Brendon M Stiles; Mohamed K Kamel; Abu Nasar; Sebron Harrison; Andrew B Nguyen; Paul Lee; Jeffrey L Port; Nasser K Altorki
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

2.  Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.

Authors:  Abel Gómez-Caro; Samuel Garcia; Noemí Reguart; Pedro Arguis; Marcelo Sanchez; Josep M Gimferrer; Ramon Marrades; Francisco Lomeña
Journal:  Eur J Cardiothorac Surg       Date:  2010-01-29       Impact factor: 4.191

3.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

4.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

Authors:  Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Kei Suzuki; Stefan S Kachala; Emily C Zabor; Camelia S Sima; Andre L Moreira; Akihiko Yoshizawa; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Mod Pathol       Date:  2012-04-13       Impact factor: 7.842

6.  Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer.

Authors:  K Suzuki; K Nagai; J Yoshida; M Nishimura; K Takahashi; Y Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  1999-03       Impact factor: 5.209

7.  Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.

Authors:  Carolyn E Reed; David H Harpole; Katherine E Posther; Sandra L Woolson; Robert J Downey; Bryan F Meyers; Robert T Heelan; Homer A MacApinlac; Sin-Ho Jung; Gerard A Silvestri; Barry A Siegel; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

8.  Impact of free tumor clusters on prognosis after resection of pulmonary adenocarcinoma.

Authors:  Junichi Morimoto; Takahiro Nakajima; Hidemi Suzuki; Kaoru Nagato; Takekazu Iwata; Shigetoshi Yoshida; Masaki Fukuyo; Satoshi Ota; Yukio Nakatani; Ichiro Yoshino
Journal:  J Thorac Cardiovasc Surg       Date:  2016-07       Impact factor: 5.209

9.  Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement.

Authors:  Yi-Chen Yeh; Jun-ichi Nitadori; Kyuichi Kadota; Akihiko Yoshizawa; Natasha Rekhtman; Andre L Moreira; Camelia S Sima; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Histopathology       Date:  2015-02-05       Impact factor: 5.087

10.  Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Authors:  Takashi Eguchi; Koji Kameda; Shaohua Lu; Matthew J Bott; Kay See Tan; Joseph Montecalvo; Jason C Chang; Natasha Rekhtman; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2018-09-19       Impact factor: 15.609

View more
  13 in total

Review 1.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Platelet Count is Associated with the Rate of Lymph Node Metastasis in Lung Adenocarcinoma.

Authors:  Cheng-Hao Qu; Tong Li; Zhan-Peng Tang; Xi-Rui Zhu; Jing-Yi Han; Hui Tian
Journal:  Cancer Manag Res       Date:  2020-10-07       Impact factor: 3.989

3.  Clinicopathological Impact of the Spread through Air Space in Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jung-Soo Pyo; Nae Yu Kim
Journal:  Diagnostics (Basel)       Date:  2022-04-28

4.  Lung cancer with PET/CT-defined occult nodal metastasis yields favourable prognosis and benefits from adjuvant therapy: a multicentre study.

Authors:  Jiajun Deng; Yifan Zhong; Tingting Wang; Minglei Yang; Minjie Ma; Yongxiang Song; Yunlang She; Chang Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-20       Impact factor: 10.057

5.  Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study.

Authors:  Donglai Chen; Xiaofan Wang; Fuquan Zhang; Ruoshuang Han; Qifeng Ding; Xuejun Xu; Jian Shu; Fei Ye; Li Shi; Yiming Mao; Yongbing Chen; Chang Chen
Journal:  Ther Adv Med Oncol       Date:  2020-12-14       Impact factor: 8.168

Review 6.  Spread through air spaces positivity and extent of resection in patients with Stage I non-small cell lung cancer: A contemporary review.

Authors:  Ulaş Kumbasar
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2022-01-28       Impact factor: 0.332

7.  Preoperative risk factors of lymph node metastasis in clinical N0 lung adenocarcinoma of 3 cm or less in diameter.

Authors:  Cheng Fang; Yangwei Xiang; Weili Han
Journal:  BMC Surg       Date:  2022-04-29       Impact factor: 2.030

8.  Genomics Analysis and Nomogram Risk Prediction of Occult Lymph Node Metastasis in Non-Predominant Micropapillary Component of Lung Adenocarcinoma Measuring ≤ 3 cm.

Authors:  Kun Wang; Mengchao Xue; Jianhao Qiu; Ling Liu; Yueyao Wang; Rongyang Li; Chenghao Qu; Weiming Yue; Hui Tian
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

9.  Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma.

Authors:  Raul Caso; James G Connolly; Jian Zhou; Kay See Tan; James J Choi; Gregory D Jones; Brooke Mastrogiacomo; Francisco Sanchez-Vega; Bastien Nguyen; Gaetano Rocco; Daniela Molena; Smita Sihag; Prasad S Adusumilli; Matthew J Bott; David R Jones
Journal:  NPJ Precis Oncol       Date:  2021-07-21

10.  Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces.

Authors:  Yu Tian; Jing Feng; Long Jiang; Junwei Ning; Zenan Gu; Jia Huang; Qingquan Luo
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.